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Abstract
Background: Pregnancies complicated by abnormal umbilical artery Doppler blood flow patterns
often result in the baby being born both preterm and growth-restricted. These babies are at high
risk of milk intolerance and necrotising enterocolitis, as well as post-natal growth failure, and there
is no clinical consensus about how best to feed them. Policies of both early milk feeding and late
milk feeding are widely used. This randomised controlled trial aims to determine whether a policy
of early initiation of milk feeds is beneficial compared with late initiation. Optimising neonatal
feeding for this group of babies may have long-term health implications and if either of these policies
is shown to be beneficial it can be immediately adopted into clinical practice.
Methods and Design: Babies with gestational age below 35 weeks, and with birth weight below
10th centile for gestational age, will be randomly allocated to an "early" or "late" enteral feeding
regimen, commencing milk feeds on day 2 and day 6 after birth, respectively. Feeds will be gradually
increased over 9-13 days (depending on gestational age) using a schedule derived from those used
in hospitals in the Eastern and South Western Regions of England, based on surveys of feeding
practice. Primary outcome measures are time to establish full enteral feeding and necrotising
enterocolitis; secondary outcomes include sepsis and growth. The target sample size is 400 babies.
This sample size is large enough to detect a clinically meaningful difference of 3 days in time to
establish full enteral feeds between the two feeding policies, with 90% power and a 5% 2-sided
significance level. Initial recruitment period was 24 months, subsequently extended to 38 months.
Discussion: There is limited evidence from randomised controlled trials on which to base
decisions regarding feeding policy in high risk preterm infants. This multicentre trial will help to
guide clinical practice and may also provide pointers for future research.
Trial registration: Current Controlled Trials ISRCTN: 87351483
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Background
The purpose of this trial is to gain a better understanding
of methods of establishing enteral feeding in high-risk
preterm infants.
Preterm infants are at increased risk of adverse neonatal
outcomes. At particular risk are those infants born after
pregnancies in which Doppler studies of umbilical arterial
wave forms reveal absent or reversed end diastolic flow
velocities (AREDFV) [1]. This phenomenon occurs in
approximately 6% of high risk pregnancies [2] and is
believed to result from increased placental vascular resist-
ance in response to both acute and chronic hypoxia. Lack
of oxygen results in intrauterine growth restriction (IUGR)
and the baby is often delivered preterm and small for ges-
tational age. The prognosis is poor compared to those
with normal antenatal Doppler studies [1-5]. In infants
with abnormal umbilical artery Doppler blood flow
velocities it has been shown that blood flow to the head
tends to be preserved to support growth of the brain at the
expense of blood flow to the abdomen and growth of vis-
ceral organs [3,6,7]. In the earlier stages of fetal hypoxia
(before AREDFV occurs) the changes of cerebral redistri-
bution may be seen, with widening of the ratio of blood
flow velocity in the cerebral artery to that in the umbilical
artery - the cerebro-placental ratio. An increase in this
ratio has also been associated with increased perinatal
morbidity [8-10].
Feeding babies born after AREDFV is a challenge: they are
already under-nourished at birth, and good nutrition and
growth is essential. However they frequently demonstrate
intolerance of milk feeds and have been shown to have an
increased incidence of necrotising enterocolitis (NEC)
[1,3]. NEC is the commonest serious gastrointestinal
emergency in neonatal intensive care units [11] and is
associated with a high mortality and morbidity [12,13].
Extreme prematurity is the greatest risk factor, and whilst
the specific aetiology is often not clear in individual
babies, under perfusion and/or hypoxia of the gut are
thought to be important predisposing factors [14]. Enteral
feeding and bacterial invasion are commonly associated
factors [14,15]. Reduced gut blood flow due to splanchnic
vasoconstriction [1,3] may cause hypoxic-ischaemic dam-
age to the intestine or its mucosa predisposing to NEC.
Additionally, these conditions may affect normal motor,
secretory and mucosal development so that the intestine
is more susceptible to stasis, abnormal colonisation and
bacterial invasion postnatally. IUGR is associated with
bone marrow suppression and neutropenia in early post-
natal life, which may also increase susceptibility to infec-
tive factors. Babies born after absent EDFV were found to
have reduced flow velocities in the coeliac and superior
mesenteric arteries compared with birthweight or gesta-
tional age matched controls [16]. Flow velocities
improved but differences were still apparent on day 7 of
life. A subsequent study showed impaired dynamic
response in the superior mesenteric artery to the first milk
feed in this group [17].
A recent meta-analysis [18] identified 14 observational
studies [1,3,5,19-29] comparing the incidence of NEC in
infants who had exhibited fetal AREDFV with a group of
controls. Nine of these studies show an excess of NEC in
the AREDFV infants, with an overall odds ratio for devel-
oping NEC of 2.13 (95% CI 1.49-3.03) compared with
controls with forward fetal umbilical end-diastolic flow.
The incidence of NEC varies depending on the specific
population. In the fourteen studies described above,
including a total of 659 infants, the incidence varied
between 0-59%, with an average of 12.9%. Among 2681
babies with birthweight 501-1500 grams born in, or trans-
ferred to, hospitals participating in the NICHD Neonatal
Network between February 1988 and August 1989 the
incidence of 'proven NEC' was 10.5%, with 'suspected
NEC' at 17.2% [30]. The Vermont Oxford Network LBW
Database (infants 401-1500 grams) shows an overall inci-
dence of proven NEC (clinical and radiographic diagno-
sis) of 6% (VON Annual Reports 2002 and 2003).
Analysis of the Network data previously showed an
increased risk of NEC in babies with evidence of IUGR
(birthweight below 10th centile): OR 1.27 (95% CI 1.05-
1.53) [31] but information on antenatal Doppler studies
is not collected.
There is no consensus regarding how best to prevent NEC
in small, preterm infants. Several strategies of poorly
proven efficacy are in use, including delaying feeds, slowly
increasing feeds, use of total parenteral nutrition (TPN)
and prophylactic antibiotics [32-34]. A systematic review
of prophylactic antibiotic use published in the Cochrane
Library demonstrated a statistically significant reduction
in NEC, but also a significant increase in the incidence of
colonisation with resistant bacteria and concluded that
there was insufficient evidence to support this approach
in clinical practice [35].
The timing of introduction and rate of progression of milk
feeds is an area of clinical uncertainty with arguments in
favour of both early and late introduction of enteral feeds.
Early introduction may improve nutrition and growth,
but may increase the risk of NEC [30,32]. Conversely late
introduction may be detrimental due to lack of stimula-
tion of the gastrointestinal tract, resulting in villous atro-
phy and lack of hormone and enzyme production [30,36]
and may not reduce the incidence of NEC [37,38]. Pro-
longed use of parenteral nutrition increases the risks of
sepsis, cholestatic jaundice and vitamin and mineral defi-
ciencies [39-41]. IUGR infants are at particularly high risk
of parenteral nutrition-related liver disease [42].
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The use of minimal enteral nutrition (MEN) (trophic
feeds, gut-priming, non-nutritive feeding) has increas-
ingly been used in the early feeding of preterm infants and
appears to be well tolerated and beneficial in terms of gut
motility, earlier establishment of substantive milk feeding
and reduced cholestasis [43-49]. A systematic review pub-
lished in the Cochrane Library [50] included eight ran-
domised controlled trials and found that infants receiving
MEN had an overall reduction in the time taken to achieve
full enteral feeding and in the length of hospital stay.
Regarding the effect on NEC the reviewers concluded that
although no discernable effect was seen an increased risk
of NEC could not be excluded - the risk ratio of NEC with
MEN was 1.10 (95% CI 0.63-1.90).
Since this review was last updated in 1997, three further
trials of MEN have been published. Van Elburg [51] spe-
cifically studied babies who were IUGR. Fifty six babies
with birthweight below 2000 grams, and below the 10th
centile for gestational age, were randomised to receive
either MEN (minimal enteral feeds - MEF) starting within
48 hours of birth, or no feeds for the first five days of life
(NEF). Among the 42 who completed the trial there was
no significant difference between groups in the primary
outcome of intestinal permeability using a sugar absorb-
ance test (p = 0.14). There was no difference in secondary
outcomes of days to reach full feeds (p = 0.32), days to
regain birthweight (p = 0.78) or NEC (0/20 cases in MEF
group, 1/22 cases in NEF group (p = 0.76)). In those
babies in whom it was measured (25/42), the ratio of
umbilical artery to cerebral artery pulsatility index was not
predictive of feeding tolerance (p = 0.55). In the two fur-
ther trials McClure studied 100 infants, seeing 1 and 2
cases of NEC in MEN and control infants respectively
[52]. Schanler's trial contained 171 infants, with 13 cases
of NEC in the MEN group, compared to 10 cases in the
control infants [53]. Combining these results with those
of the Tyson meta-analysis, in 692 infants, NEC rates are
similar at 10.5% for MEN and 9.4% for control infants
(RR 1.07, 95% CI 0.84, 1.36).
The duration of MEN and subsequent rate of advance-
ment is another area of uncertainty. Several studies have
suggested that increasing feeds by 30-35 ml/kg/day is as
safe as a slower rate of 15-20 ml/kg/day [54,55]. A trial of
MEN versus progressive feeding in infants less than 32
weeks gestation was stopped early because of an increased
incidence of NEC in the progressive feeding group [56]. In
this study however feeds were started late in both groups
(mean 10.3 and 9.3 days), and were given as two-hourly
infusions followed by 2-hourly fasts. In addition breast
milk fortifier was added when feeds of 120 ml/kg/day
were reached and doubled when feeding volume reached
140 ml/kg/day.
There is thus no clear evidence to guide the choice of early
or late introduction of enteral feeding in high risk IUGR
infants. Practice varies widely as was discovered in surveys
of neonatal units in two English health regions. In the
Southwest enteral feeding was delayed in 9/12 hospitals
for IUGR babies of less than 32 weeks gestation ('always'
in three, 'usually' in six), and 'usually' in four hospitals for
babies at 32-36 weeks. Feeds were delayed for less than
five days in five hospitals, greater than five in one hospital
and for variable duration in five. Abnormal Dopplers,
polycythaemia, presence of umbilical artery catheter and
the absence of breast milk made delay more likely. Within
the 15 hospitals in the Eastern Region five units com-
menced feeds on day one, two delayed until day 7, with
the remainder commencing feeds between day 2 and 5.
The main reason cited for delaying feeds is to try to pre-
vent NEC.
Aim
We aim to evaluate the effects of an "early" enteral feeding
regimen, starting milk feeds on day 2 after birth (between
24 and 48 hours of age) compared to one of "late" intro-
duction of enteral feeds, starting feeds on day 6 after birth
(between 120-143 hours of age) in a group of babies iden-
tified as being at high risk for NEC and milk intolerance
by antenatal Doppler studies.
Methods and Design
Ethics Committee Approval
UK Multicentre Research Ethics Committee approval was
initially granted in September 2005 with subsequent
approvals for protocol amendment; this latest version was
approved in January 2008.
Eligibility and exclusions
Hospital eligibility
Hospitals will be eligible to participate in the ADEPT trial
providing there are facilities for antenatal Doppler ultra-
sound of high risk pregnancies and that these are per-
formed with appropriate filter settings, and facilities for
neonatal high dependency care including parenteral
nutrition.
Infant eligibility
Infants admitted to participating neonatal units and satis-
fying all of the following criteria may be recruited into the
study:
1) Gestational age up to and including 34 weeks + 6 days
(dated by antenatal ultrasound or clinically).
2) Antenatal ultrasound showing either
a) absent or reversed end diastolic flow velocities on at
least 50% of the Doppler waveforms from the umbili-
cal artery on at least one occasion during pregnancy
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or
b) cerebral redistribution, defined as occurring when
both the umbilical artery pulsatility index is greater
than the 95th centile and the middle cerebral artery
pulsatility index is less that the 5th centile for gesta-
tional age [9].
3) Small for gestational age (birth weight < 10th centile for
gestational age based on Child Growth Foundation
Charts [57]).
4) Postnatal age 20-48 hours
Infants will be excluded if any of the following factors are
present:
• major congenital abnormality including known
chromosomal abnormality
• twin-twin transfusion
• intra-uterine transfusion or exchange transfusion
• Rhesus iso-immunisation
• significant multi-organ failure prior to trial entry
• inotropic drug support prior to trial entry
• already received any enteral feeding
Recruitment and randomisation
Informed written consent for the trial will be obtained
from the parents in the first 2 days after birth. This will
preferably be in the first 24 hours after birth. The parents
will be given a verbal explanation of the study and a writ-
ten information sheet, and will have an opportunity to
discuss participation with the recruiting clinician. If con-
sent is given, and providing no contra-indications occur,
the baby should then be randomised between 20 and 48
hours of age. Babies will be randomised to study groups
by a central randomisation service, based at the National
Perinatal Epidemiology Unit (NPEU), University of
Oxford. The randomisation service (website with tele-
phone back-up facility) will request details of the baby
and, if eligible, will provide a random allocation to one of
the study groups, either "early" or "late" commencement
of enteral feeds. The program will use minimisation to
ensure balance between the groups with respect to hospi-
tal of recruitment, gestational age (< 29 completed weeks
or ≥ 29 completed weeks) and type of Doppler abnormal-
ity (AREDFV or cerebral redistribution).
Interventions
Babies will be randomly allocated to an "early" or "late"
enteral feeding regimen. These will start milk feeds on day
2 and day 6 after birth, respectively. The regimens for the
two groups are based on those currently used in hospitals
in the Eastern and South Western Regions, according to a
survey of practice carried out in 1999.
The two regimens are as follows:
'Early' and 'Late' Feeding Regimens: see Table 1
For the purposes of the study the choice of milk recom-
mended to mothers to feed their baby should be, in
descending order of preference: mother's own breast milk,
donated breast milk, infant formula (all dependent on
availability). Whether preterm or term formula is the for-
mula given initially will be at the discretion of the local
clinician but the recommendation would be for infants
with gestation less than 34 weeks to be fed preterm for-
mula within one week of milk commencement. The final
choice of which milk is used will rest with the infant's
mother. Breast milk fortification may be considered if
additional nutritional support is required once the baby is
tolerating full milk feeds of breast milk of ≥ 150 ml/kg/
day.
The feeding schedule of each group should be followed
regardless of the type of milk available, ventilation status,
or presence of an UAC unless specifically requested by the
local clinician. The decision to withhold feeds or deviate
from the feeding schedule in Tables 2 and 3, because of
apparent feed intolerance or clinical deterioration, will
also remain at the local clinician's discretion. Gastric
residuals are not uncommon in preterm infants [58]. Pro-
viding the infant is well and has no abnormal abdominal
signs it is usually safe to continue with enteral feeds when
Table 1: 'Early' and 'Late' Feeding Regimens
Feed regimen 'early' 'late'
0-24 hours: day 1 Nil by mouth Nil by mouth
24-48 hours: day 2 Start milk feeds according to tables 2 & 3 Nil by mouth
48-119 hours: day 3-5 Progress with feeding according to tables 2 & 3 Nil by mouth
120-143 hours: day 6 Progress with feeding according to tables 2 & 3 Start milk feeds according to tables 2 & 3
144 hours onwards - day 7+ Progress with feeding according to tables 2 & 3 Progress with feeding according to tables 2 & 3
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gastric aspirate is 2-3 ml or less (2 ml in a baby of less than
750 grams birth weight). If feed volumes are withheld or
there is any deviation from the schedule in Tables 2 and 3
then the clinician is free to either start again from day 1,
re-start at the volume previously tolerated then increase as
scheduled daily, or hold for one or more days at a certain
volume and then increase as scheduled.
Other clinical management
Clinical management will include commencement of
intravenous parenteral nutrition (glucose, amino acids
and intralipid) by the second or third day after birth for all
babies. All other aspects of care will be according to local
routine practice.
Outcomes
Primary outcome measures
1. Age in days at which full enteral feeding sustained for
72 hours was reached.
2. Necrotising enterocolitis, stage I, II or III [11] (Appen-
dix 1)
Secondary outcome measures
• Death before hospital discharge
• Duration of hospital stay
• Duration of intensive and high dependency care
(Appendix 2)
Table 2: Feeding schedule - ml/kg/HOUR
Day of feeding Volume of milk according to birth weight (ml/kg/HOUR)
< 600 g 600-749 g 750-999 g 1000-1249 g ≥ 1250 g
1 0.5 0.5 0.5 0.5 1.0
2 0.5 0.5 0.5 1.0 1.5
3 0.5 1.0 1.0 1.5 2.0
4 1.0 1.5 1.5 2.0 2.5
5 1.5 2.0 2.0 2.5 3.0
6 2.0 2.5 2.5 3.0 3.5
7 2.5 3.0 3.0 3.5 4.0 - 4.5
8 3.0 3.5 3.5 4.0 - 4.5 5.0 - 5.5
9 3.5 4.0 4.0 - 4.5 5.0 - 5.5 6.0 - 6.25
10 4.0 4.5 - 5.0 5.0 - 5.5 6.0 - 6.25
11 4.5 - 5.0 5.5 - 6.0 6.0 - 6.25
12 5.5 - 6.0 6.25
13 6.25
14 Increase as required
(NB feed advancement schedule is the same for babies in EARLY or LATE groups: only the timing of initiation of feeds differs)
Where 2 numbers are in a cell separated by a hyphen the first number indicates hourly volume/kg to feed for the first 12 hours of each 24 hour 
period. The second number in each cell indicates hourly volume/kg to feed for the second 12 hours of each 24 hour period.
Feeds should be given hourly or continuously. However, if there are longer intervals between feeds, e.g. 2 hourly feeds, then the milk volume 
should be increased accordingly.
Light grey background = feeds increase by 0.5 ml/kg every 12 hours.
Dark grey background = feed volume reached 150 ml/kg/day (6.25 ml/kg/hour).
Feeds can be increased as required.
BMC Pediatrics 2009, 9:63 http://www.biomedcentral.com/1471-2431/9/63
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• Duration of parenteral nutrition
• Change in Z score for weight and head circumference
from birth to 36 weeks post-
conceptional age and from birth to discharge
• In continuous supplemental oxygen at 36 weeks post-
menstrual age
• Confirmed bacterial sepsis (Appendix 3)
• Gastrointestinal perforation
• Gastrointestinal surgery
• Cholestasis (defined as >25 μmol/l conjugated fraction
of serum bilirubin)
• Patent ductus arteriosus requiring pharmacological or
surgical treatment
• Cranial ultrasound abnormality
• Type of milk at discharge
• On oxygen therapy at discharge
No additional blood tests will be performed because of
this study.
Data collection
Data will be collected at trial entry, during the infant's stay
in the neonatal unit, and at discharge. At trial entry base-
line data and eligibility information will be collected and
returned to the co-ordinating centre. Information col-
lected during the infant's stay in the neonatal unit will
include enteral feeding history (to assess compliance) and
other treatments given (to assess whether interventions
are used differentially in the two groups). This is impor-
tant because caregivers will not be blinded to the ran-
domised allocations. Outcome data will be recorded on a
form competed by clinicians at discharge. To facilitate
later tracing for follow-up and enable notification of any
Table 3: Feeding schedule - ml/kg/DAY (NB feed advancement schedule is the same for babies in EARLY or LATE groups: only the 
timing of initiation of feeds differs).
Day of feeding Volume of milk according to birth weight (ml/kg/DAY)
<600 g 600-749 g 750-999 g 1000-1249 g ≥ 1250 g
1 12 12 12 12 24
2 12 12 12 24 36
3 12 24 24 36 48
4 24 36 36 48 60
5 36 48 48 60 72
6 48 60 60 72 84
7 60 72 72 84 96 - 108
8 72 84 84 96 - 108 120-132
9 84 96 96-108 120-132 144-150
10 96 108-120 120-132 144-150
11 108-120 132-144 144-150
12 132-144 150
13 150
14 Increase as required
BMC Pediatrics 2009, 9:63 http://www.biomedcentral.com/1471-2431/9/63
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deaths, all infants recruited to the study will be flagged at
the NHS Central Register.
All data required for trial analysis will be routinely col-
lected in medical and nursing charts.
Perinatal and early neonatal data will be submitted to the
ADEPT Co-ordinating Centre at time of trial entry. Subse-
quent neonatal data and outcome data will be submitted
at discharge and on transfer to a different neonatal unit if
applicable. Growth data - weight and head circumference -
will be collected at 36 weeks post-menstrual age and at
discharge.
Serious Adverse Event and Suspected Unexpected Serious 
Adverse Reaction reporting
Serious Adverse Events and Suspected Unexpected Serious
Adverse Reactions should be reported to the ADEPT co-
ordinating office within 48 hours. The co-ordinating
office will then report it to the Chair of the DMEC and the
MREC with a summary of the previously reported events
within 15 days. As both early and late feeding policies are
already used in different hospitals within the UK there are
no SAEs which would be anticipated as a unique conse-
quence of participation in the trial. We would however
expect the following to be reported:
• All deaths
• Severe central venous line complication: cardiac
tamponade, major vessel thrombosis
Any other serious unexpected adverse events
Statistical analysis
Analysis will be by intention to treat i.e. all babies will be
analysed in their allocated groups, regardless of the treat-
ment they actually received. For dichotomous outcomes,
relative risks and 95% confidence intervals will be calcu-
lated. For continuous outcomes, differences in means or
differences in medians (depending on the distribution of
the data) will be calculated along with 95% confidence
intervals. Analysis of time to event outcomes such as time
to reach full enteral feeding and duration of stay in hospi-
tal will use survival analysis techniques.
Two pre-specified subgroup analyses will be conducted,
stratifying by (a) gestational age at birth (< or ≥ 29 weeks)
and (b) type of Doppler abnormality (AREDFV or cerebral
redistribution). Statistical tests of interaction will be used
for the subgroup analyses. Interim analyses will be con-
ducted at least once per year during the period of recruit-
ment, and reviewed in confidence by a Data Monitoring
Committee.
Interim analysis
A Data Monitoring Committee (DMC), independent of
the trial investigators, has been established. The DMC
terms of reference, including the statistical stopping rules,
have been agreed and are documented in the ADEPT DMC
Charter. During the period of recruitment to the trial,
interim analyses will be supplied in strict confidence to
the DMC as frequently as they request. Meetings of the
committee will be at least once a year as considered appro-
priate by the Chair.
In the light of interim data, and other evidence from rele-
vant studies (including updated overviews of the relevant
randomised controlled trials), the DMC will inform the
Trial Steering Committee, if in their view there is proof
beyond reasonable doubt that the data indicate that any
part of the protocol under investigation is either clearly
indicated or contra-indicated, either for all or for a partic-
ular subgroup of trial participants.
Unless modification or cessation of the protocol is recom-
mended by the DMC, the Trial Steering Committee, col-
laborators and administrative staff (except those who
supply the confidential information) will remain ignorant
of the results of the interim analysis. Collaborators and all
others associated with the study may write through the
study co-ordinating centre to the DMC, to draw attention
to any concern they may have about the possibility of
harm arising from the treatment under study, or about
any other matters that may be relevant.
Membership of the Data Monitoring Committee
Professor Richard Cooke (Chair)
Dr Simon Newell
Dr John Puntis
Ms Ly-Mee Yu
Establishment of a blinded endpoint committee
As a result of central monitoring the trial data, it has
become clear that the primary end point has not been
achieved in a small number of cases. There are two main
reasons for this:
i) the introduction of breast-feeding
ii) completion of the feeding log has stopped prematurely
in the mistaken belief that the primary endpoint has been
reached
Where there is uncertainty as to whether the primary end-
point has been reached, a committee has been established
to consider each case and recommend an appropriate
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course of action. The committee will be blind to alloca-
tion.
Membership of the Blinded Endpoint Committee
Dr Alison Leaf.
Dr Kenny McCormick.
Dr Steve Kempley.
Sample size
Using unpublished data from the Eastern Region Very
Low Birthweight database, which suggests a standard devi-
ation of 9 days in the time taken to reach full enteral feed-
ing, about 380 infants will be required to show a
difference of 3 days in this outcome with 90% power. The
incidence of NEC is about 15% in this population and a
sample of 400 would be sufficient to show a reduction to
7.5% with 60% power. NEC is retained as a primary out-
come because of its clinical importance for this group of
babies. We acknowledge that the power to detect relatively
small differences will be limited. The target sample size is
400 babies, to be recruited over 24 months.
Feasibility
There is little information on the number of babies that
may be eligible for this trial. We estimate that each partic-
ipating hospital may have around 10-30 eligible babies
per year depending on obstetric case mix. If an average
hospital has 15 eligible babies per year and a third of these
can be recruited (i.e. 5 recruits/hospital/year), around 40
hospitals will need to participate to complete recruitment
of 400 babies in 2 years.
Organisation
The trial will be overseen by a Trial Steering Committee,
consisting of the Investigators and the project team at
NPEU plus independent members. This group will meet
regularly throughout the trial to review progress and
resolve problems, receive reports from the Data Monitor-
ing Committee and take decisions about the trial's con-
duct.
The trial co-ordinating centre will be at the NPEU, where
the Trial Co-ordinator will be based. The NPEU will be
responsible for day to day co-ordination of the trial,
including recruitment of hospitals to the study, program-
ming, data management, and statistical analysis.
Membership of the Trial Steering Committee
The Membership of the Trial Steering Committee is listed
in Table 4
Local co-ordination
Each participating centre will identify a site specific prin-
cipal investigator to act as local co-ordinator for that cen-
tre. Their responsibilities will be to:
i) be familiar with the trial
ii) liaise with the Trial Co-ordinating centre in Oxford
iii) ensure that all staff involved in the care of eligible
babies are informed about the trial
iv) ensure that mechanisms for recruitment of eligible
babies (including information material) are in place,
monitor their effectiveness, and discuss reasons for the
non-recruitment with relevant staff
v) ensure that supplies of data collection forms are availa-
ble, that they are completed and returned to the Trial Co-
ordinating centre promptly, and to deal with any queries
arising
vi) notify the Trial Co-ordinating centre of any serious
adverse events
vii) make all data available for verification, audit and
inspection purposes as necessary
viii) ensure that the confidentiality of all information
about trial participants is respected by all persons.
Competing interests
The authors declare that they have no competing interests.
Table 4: Membership of the Trial Steering Committee
Professor Zarko Alfirevic Consultant in Obstetrics & Gynaecology Chair
Dr Andrew Ewer Consultant Neonatologist Independent member
Ms Pauline Fellows NSC Neonatal Project Facilitator Independent member
Professor Khalid Khan Consultant in Obstetrics & Gynaecology Independent member
Dr Alison Leaf Consultant Neonatologist & Speciality Director Clinical Lead
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Appendix 1: Modified Bell's criteria from Walsh 
MC et al 1986
Stage IA - Suspected NEC
Systemic signs: temperature instability, apnoea, brady-
cardia, lethargy
Intestinal signs: Elevated pre-gavage residuals, mild
abdominal distension, emesis, haem-positive stools
Radiologic signs: Normal or intestinal dilatation, mild
ileus
Stage IB - Suspected NEC
Systemic signs: Same as stage IA
Intestinal signs: bright red blood from rectum
Radiologic signs: same as stage IA
Stage IIA - Definite NEC (mildly ill)
Systemic signs: Same as stage IA
Intestinal signs: Same as stage IA, plus absent bowel
sounds, +/- abdominal tenderness
Radiologic signs: intestinal dilatation, ileus, pneuma-
tosis intestinalis
Stage IIB - Definite NEC (moderately ill)
Systemic signs: Same as stage IIA, plus mild metabolic
acidosis, mild thrombocytopenia
Intestinal signs: Same as stage IIA, plus absent bowel
sounds, definite abdominal tenderness, +/- abdomi-
nal cellulitis or right lower quadrant mass
Radiologic signs: Same as stage IIA plus portal vein
gas, +/- ascites
Stage IIIA - Advanced NEC (severely ill, bowel intact)
Systemic signs: Same as stage IIB, plus hypotension,
bradycardia, severe apnea, combined respiratory and
metabolic acidosis, DIC, neutropenia
Intestinal signs: Same as stage IIB, plus signs of gener-
alized peritonitis, marked tenderness, and distension
of abdomen
Radiographic signs: Same as stage IIB, plus definite
ascites
Stage IIIB - Advanced NEC (severely ill, bowel perforated)
Systemic signs: Same as stage IIIA
Intestinal signs: Same as IIIA
Radiologic signs: Same as stage IIB, plus pneumoperi-
toneum
Appendix 2: Definition of levels of neonatal 
intensive care (BAPM 2001)
Intensive Care includes babies
Receiving any respiratory support via a tracheal tube and
in the first 24 hours after its withdrawal
Receiving NCPAP for any part of the day and less than five
days old
Below 1000 g current weight and receiving NCPAP for any
part of the day and for 24 hours after withdrawal
Less than 29 weeks gestational age and less than 48 hours
old
Requiring major emergency surgery, for the pre-operative
period and post-operatively for 24 hours
On the day of death
Requiring complex clinical procedures:
• Full exchange transfusion
• Peritioneal dialysis
• Infusion of an inotrope, pulmonary vasodilator or
prostaglandin and for 24 hours afterwards
Any other very unstable baby considered by the nurse-in-
charge to need 1:1 nursing
High dependency care includes babies
Receiving NCPAP for any part of the day and not fulfilling
any of the criteria for intensive care
Below 1000 g current weight and not fulfilling any of the
criteria for intensive care
Requiring parenteral nutrition
Having convulsions
Receiving oxygen therapy and below 1500 g current
weight
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Requiring treatment for neonatal abstinence syndrome
Requiring specified procedures that do not fulfil any crite-
ria for intensive care:
• Care of an intra-arterial catheter or chest drain
• Partial exchange transfusion
• Tracheostomy care until supervised by the parent
Requiring frequent stimulation for severe apnoea
Appendix 3 - Definition of infection
Symptomatic baby with positive culture of blood, CSF, or
other normally sterile site, and with haematological mark-
ers of infection including one or more of the following:
raised CRP, high or low white blood cell count, thrombo-
cytopenia.
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